Metastatic Renal Cell Carcinoma – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Metastatic Renal Cell Carcinoma – Drugs In Development, 2023’, provides an overview of the Metastatic Renal Cell Carcinoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Metastatic Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Renal Cell Carcinoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma
- The report reviews pipeline therapeutics for Metastatic Renal Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Renal Cell Carcinoma therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Renal Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Renal Cell Carcinoma
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
23andMe Holding CoAffiliated Hospital of Xuzhou Medical University
Affimed GmbH
Akeso Inc
Allarity Therapeutics Inc
Alligator Bioscience AB
Allogene Therapeutics Inc
Alphamab Oncology
Amgen Inc
Asher Biotherapeutics Inc
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Beijing Scitech-MQ Pharmaceuticals Ltd
Betta Pharmaceuticals Co Ltd
Bio-Thera Solutions Ltd
Biocon Ltd
BioIntegrator
BioXpress Therapeutics SA
Bristol-Myers Squibb Co
CanWell Pharma Inc
Centre Leon Berard
Chongqing Precision Biotech Co Ltd
Chugai Pharmaceutical Co Ltd
Concentra Biosciences LLC
Corvus Pharmaceuticals Inc
CRISPR Therapeutics AG
Daiichi Sankyo Co Ltd
Debiopharm International SA
Dragonfly Therapeutics Inc
DynamiCure Biotechnology LLC
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Co
EORTC Genito-Urinary Cancers Group
EpimAb Biotherapeutics Inc
Epygen Biotech Pvt Ltd
Evopoint Bioscience Co Ltd
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fujian Cancer Hospital
Gedeon Richter Plc
Genenta Science SpA
Genentech USA Inc
Generium
Genuv Inc
Gilead Sciences Inc
Ginkgo BioWorks Inc
Hangzhou Sumgen Biotech Co Ltd
Harbour BioMed (Guangzhou) Co Ltd
Herlev Hospital
Huabo Biopharm (Shanghai) Co Ltd
Hutchison MediPharma Ltd
ImmuneSensor Therapeutics Inc
Incyte Corp
Infinity Pharmaceuticals Inc
Innovent Biologics Inc
Invectys SA
Janux Therapeutics Inc
Jazz Pharmaceuticals Plc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kidswell Bio Corp
Kintor Pharmaceutical Ltd
Kura Oncology Inc
Lycera Corp
Mabpro as
Mendus AB
Merck & Co Inc
Merck KGaA
Mirati Therapeutics Inc
Molecular Templates Inc
Molecure SA
Mycenax Biotech Inc
National Cancer Institute US
NeoTX Therapeutics Ltd
NiKang Therapeutics Inc
Novartis AG
NuCana Plc
OncoC4 Inc
Oncorena AB
Pfizer Inc
PharmAbcine Inc
PlantForm Corp
Portage Biotech Inc
ProfoundBio Suzhou Co Ltd
Qilu Puget Sound Biotherapeutics Corp
Recombio SL
Regeneron Pharmaceuticals Inc
Sapphire Biotech Inc
Scancell Holdings Plc
Shanghai Junshi Biosciences Co Ltd
Shanghai LiteDD Co Ltd
Shanghai SunTerra Biotechnology Ltd
Sillajen Biotherapeutics
T-Cure Bioscience Inc
Telix Pharmaceuticals Ltd
Tizona Therapeutics Inc
Werewolf Therapeutics Inc
Xencor Inc
Xilio Therapeutics Inc
Xynomic Pharmaceuticals Holdings Inc